MiMedx Group Inc (MDXG) Shares are Down -2.93%

MiMedx Group Inc (MDXG) : During the past 4 weeks, traders have been relatively bearish on MiMedx Group Inc (MDXG), hence the stock is down -6.53% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.9% relative to the S&P 500. The 4-week change in the price of the stock is -6.17% and the stock has fallen -2.93% in the past 1 week.

MiMedx Group, Inc. is up 4.14% in the last 3-month period. Year-to-Date the stock performance stands at -22.09%. The stock has recorded a 20-day Moving Average of 2.99% and the 50-Day Moving Average is 5.33%.


MiMedx Group Inc (NASDAQ:MDXG): The stock opened at $7.32 on Friday but the bulls could not build on the opening and the stock topped out at $7.34 for the day. The stock traded down to $7.21 during the day, due to lack of any buying support eventually closed down at $7.30 with a loss of -0.54% for the day. The stock had closed at $7.34 on the previous day. The total traded volume was 332,592 shares.

Also, Lake Street maintains its rating on MiMedx Group Inc (NASDAQ:MDXG). The global brokerage major lowers the current price target from $15 per share to $12 per share. Analysts at the Lake Street have a current rating of Buy on the shares. The rating by the firm was issued on April 19, 2016.

MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.